|
|
|
|
| LEADER |
02078nam a2200253 u 4500 |
| 001 |
EB002136323 |
| 003 |
EBX01000000000000001274450 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
221206 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Glycopyrrolate (Cuvposa)
|h Elektronische Ressource
|b (Medexus pharmaceuticals, inc.) : indication: chronic severe drooling, neurologic (pediatric)
|
| 246 |
3 |
1 |
|a Pharmacoeconomic review report for glycopyrrolate (Cuvposa)
|
| 246 |
3 |
1 |
|a Glycopyrrolate (Cuvposa)
|
| 250 |
|
|
|a Version: Final
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, July 2020
|
| 300 |
|
|
|a 1 PDF file (28 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK565308
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Glycopyrrolate oral solution (Cuvposa) is an anticholinergic drug indicated to reduce chronic severe drooling in patients three to 18 years of age with neurologic conditions (e.g., cerebral palsy [CP]). It is available in a 1 mg/5 mL concentration in 473 mL bottles at a submitted price of $625.00 per bottle, or $6.61 per mL. The recommended starting dose of glycopyrrolate is 0.02 mg/kg three times daily, titrated in increments of 0.02 mg/kg every five to seven days based on therapeutic response and adverse reactions. The maximum recommended dose is 0.1 mg/kg three times daily, not to exceed 1.5 to 3 mg per dose (see Table 11 for further details). For a 30 kg patient, depending on dose, the daily cost of glycopyrrolate at the submitted price may range from $11.98 to $59.46 (see Table 5). The sponsor submitted a cost-utility analysis comparing glycopyrrolate oral solution to no treatment in the indicated population from the perspective of a Canadian publicly funded health care system over a 24-week time horizon
|